A new study published last Wednesday in the British Medical Journal shows there might be uses for GLP-1 medications like Ozempic beyond their applications for diabetes and weight loss. The study found that participants using GLP-1s were less likely to develop substance-use disorders or to have bad outcomes like overdosing.
This comes at a time when manufacturers of these medications are studying whether GLP-1 drugs might aid symptoms of neurological disorders like schizophrenia.
On Cincinnati Edition, we look into what the latest research suggests.
Guests:
- Dave Knapp, founder, On The Pen
- Angela Vogt, regional medical director, Groups Recover Together
Beginning at noon, call 513-419-7100 or email talk@wvxu.org to have your voice heard on this topic. You can catch a recorded replay at 8 p.m.